{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:53:43Z","timestamp":1758779623320,"version":"3.44.0"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Follicular lymphoma (FL) is an indolent yet incurable B-cell lymphoma subtype commonly treated with a combination of bendamustine and anti-CD20 antibodies such as rituximab. While the standard administration involves a 2-day dosing schedule, the COVID-19 pandemic prompted the exploration of a 1-day regimen to reduce hospital visits for immunocompromised patients. This study aimed to compare the efficacy and safety of 1-day versus 2-day bendamustine regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective analysis of 144 patients with FL, marginal zone lymphoma, mantle cell lymphoma, or Waldenstr\u00f6m macroglobulinemia treated at the Department of Internal Medicine and Hematology, Semmelweis University between 2015 and 2023. All patients received bendamustine combined with either rituximab or obinutuzumab. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS) and toxicity. Kaplan\u2013Meier survival analysis and appropriate statistical tests were applied.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The median PFS for the cohort was 69.47\u00a0months; OS was not reached. Despite receiving a significantly lower cumulative dose, and being significantly older, patients on the 1-day regimen had similar PFS (not reached vs. 69.47\u00a0months; p = 0.885) and no significant difference in OS (p = 0.147) compared to the 2-day group. Adverse events were more frequent in the 2-day regimen group, including severe side effects, such as neutropenia (p = 0.044).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A 1-day bendamustine regimen may offer comparable efficacy to the standard 2-day schedule, with a potentially more favorable toxicity profile and better convenience, especially in older or more vulnerable patient populations. These findings warrant further investigation in prospective randomized trials to establish optimal dosing strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/pore.2025.1612195","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:10:14Z","timestamp":1758777014000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Two B or not two B; the question of bendamustine dosing in low grade lymphoma"],"prefix":"10.3389","volume":"31","author":[{"given":"Eszter","family":"F\u00f6ldi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1d\u00e1m","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Szabolcs","family":"Svorenj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vir\u00e1g R\u00e9ka","family":"Szita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s D\u00e1vid","family":"T\u00f3th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilona","family":"T\u00e1rk\u00e1nyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"Feh\u00e9r","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1gnes","family":"K\u00e1rp\u00e1ti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"Szombath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsolt","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Imre","family":"Bod\u00f3","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Farkas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tam\u00e1s","family":"Masszi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gergely","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/S0140-6736(23)02705-8","article-title":"B-cell Non-Hodgkin lymphomas","volume":"403","author":"Silkenstedt","year":"2024","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11864-018-0550-0","article-title":"Follicular lymphoma: past, present, and future","volume":"19","author":"Becnel","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"B3","unstructured":"History and characterization of bendamustine\n          \n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2217\/fon-2019-0660","article-title":"Follicular lymphoma treatment patterns between 2000 and 2014: a SEER-medicare analysis of elderly patients","volume":"16","author":"Albarmawi","year":"2020","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1200\/JCO.18.00605","article-title":"First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-Year Follow-Up study","volume":"37","author":"Flinn","year":"2019","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","article-title":"Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from lymphoma study association (LYSA) centers","volume":"93","author":"Chantepie","year":"2018","journal-title":"AJH"},{"key":"B9","doi-asserted-by":"publisher","first-page":"542","DOI":"10.20471\/acc.2018.57.03.18","article-title":"Bendamustine: an old drug in the new era for patients with non-hodgkin lymphomas and chronic lymphocytic leukemia","volume":"57","author":"Bogelji\u0107 Patekar","year":"2018","journal-title":"Acta Clin Croat"},{"key":"B10","article-title":"B-Cell lymphomas","year":"2025"},{"key":"B11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40268-012-0001-5","article-title":"Pharmacokinetics and excretion of 14C-bendamustine in patients with relapsed or refractory malignancy","volume":"13","author":"Dubbelman","year":"2013","journal-title":"Drugs R D"},{"key":"B12","volume-title":"WHO classification of haematolymphoid tumours","year":"2022"},{"key":"B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00277-021-04576-y","article-title":"Reduced bendamustine for elderly patients with follicular lymphoma","volume":"101","author":"Masamoto","year":"2022","journal-title":"Ann Hematol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e70031","DOI":"10.1002\/hon.70031","article-title":"One\u2010day brentuximab\u2013bendamustine (120 mg\/m2) every 21 days is a feasible, safe and effective treatment for relapsed\/refractory hodgkin lymphoma","volume":"43","author":"Moatti","year":"2024","journal-title":"Haem Onc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e19552","DOI":"10.1200\/jco.2018.36.15_suppl.e19552","article-title":"A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma","volume":"36","author":"Paikaray","year":"2018","journal-title":"Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11523-024-01070-z","article-title":"Moving T cell therapies into the standard of care for patients with relapsed or refractory follicular lymphoma: a review","volume":"19","author":"Fowler","year":"2024","journal-title":"Targeted Oncol"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612195\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T05:10:15Z","timestamp":1758777015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1612195\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":16,"alternative-id":["10.3389\/pore.2025.1612195"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1612195","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,25]]},"article-number":"1612195"}}